Search Bar & Filters
Found 33 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating new treatment approaches for advanced ovarian cancer in people whose tumors are non-HRD positive. This study aims to find out if adding sacituzumab tirumotecan sac-TMT, a targeted therapy, as maintenance treatmentwith or without bevacizumabhelps patients live longer without their cancer worsening compared to standard care. This is a phase 3 randomized study involving participants who have completed surgery and first-line platinum-based chemotherapy. Participants receive sac-TMT intravenously on days 1, 15, and 29 of every 6-week cycle until their disease worsens or they experience prohibitive side effects. Some may also receive bevacizumab intravenously on days 1 and 22 every 6 weeks for up to 22 cycles, depending on the investigators choice. The comparison group receives either bevacizumab alone on the same schedule or is observed closely without maintenance treatment. During the study, participants will have regular evaluations to monitor their cancer status and quality of life. Researchers will measure progression-free survival for up to about 49 months and assess overall survival, adverse events, treatment discontinuation, and changes in quality of life scores for up to 78 months. Participants health will be followed long-term to understand treatment effects and safety over time.
Actively Recruiting
Researchers are studying the effectiveness and safety of combining inavolisib with a cyclin-dependent kinase 4 and 6 inhibitor CDK46i and letrozole compared to placebo with CDK46i and letrozole. This study focuses on adults with endocrine-sensitive PIK3CA-mutated hormone receptor-positive, HER2-negative advanced breast cancer. The trial is a phase III, randomized, double-blind, placebo-controlled study aiming to improve first-line treatment options for this condition. Participants will be randomly assigned to receive either oral inavolisib once daily alongside letrozole and a CDK46 inhibitor or a matching placebo with letrozole and CDK46 inhibitor. The CDK46 inhibitor is given on either days 1-21 or days 1-28 of each 28-day treatment cycle. Both groups will follow this treatment regimen throughout the study period. During the trial, participants will be monitored regularly to assess progression-free survival, overall survival, and various measures of treatment response and quality of life, including pain and physical function. Safety will be closely tracked by recording adverse events and treatment-related symptoms using patient-reported outcomes. The study may last up to seven years, including long-term follow-up to evaluate the effects of the treatments over time.
Actively Recruiting
Researchers are evaluating the efficacy and safety of combining ficlatuzumab with cetuximab compared to cetuximab alone in people with recurrent or metastatic RM HPV-negative head and neck squamous cell carcinoma HNSCC. This Phase 3, randomized, double-blind, placebo-controlled study focuses on participants who have not responded to prior anti-PD-1PD-L1 immune checkpoint inhibitors and platinum-based chemotherapy. The goal is to see if adding ficlatuzumab improves survival outcomes in this patient group. Participants are assigned to one of three groups two groups receive different doses of intravenous ficlatuzumab plus cetuximab on days 1 and 15 of each 28-day cycle, while the third group receives a placebo plus cetuximab on the same schedule. The study will enroll about 410 participants and compare progression-free survival and overall survival among these groups. Treatment cycles continue until disease progression or other study endpoints. During the study, participants will undergo regular imaging scans CT or MRI to assess tumor response every 8 weeks during the first year, then every 12 weeks in years 2 and 3, and every 6 months thereafter. Researchers will monitor safety, quality of life, and immune responses, including antidrug antibodies. The study period spans approximately 44 months with ongoing evaluations from randomization until death or last response assessment.
Actively Recruiting
Researchers are evaluating the effects of the medicine imlunestrant LY3484356 on premenopausal women with early estrogen receptor-positive, HER2-negative breast cancer. The study includes two groups one to compare imlunestrant with and without ovarian suppression against tamoxifen over up to 29 days, and another to assess imlunestrants effects on the ovaries compared to tamoxifen over up to 6 months. This phase 2 trial aims to understand treatment impacts on breast cancer cells and ovarian function. Participants receive different treatments depending on their group in Cohort 1, some take imlunestrant orally alone, some take it with subcutaneous goserelin to suppress ovarian function, and others take oral tamoxifen. In Cohort 2, participants take either oral imlunestrant or oral tamoxifen without ovarian suppression. Treatments last up to 29 days for Cohort 1 and up to 6 months for Cohort 2. During the study, participants will provide tumor samples before and during treatment, and researchers will monitor tumor markers such as Ki-67, estrogen receptor, and progesterone receptor expression. They will also track ovarian cysts over 180 days. The study includes assessments of organ function and performance status, with participant involvement lasting up to 6 months depending on the cohort.
Actively Recruiting
Researchers are studying Raludotatug Deruxtecan R-DXd, an antibody-drug conjugate that targets CDH6 protein, in people with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer. This trial includes a Phase 2 dose-optimization part to find the best dose based on safety and effectiveness, followed by a Phase 3 part comparing R-DXd to chemotherapy chosen by the investigator. Participants will receive R-DXd through an intravenous infusion every three weeks at varying doses during Phase 2. In Phase 3, participants will be randomly assigned to receive either R-DXd at the recommended dose or one of the chemotherapy options paclitaxel, pegylated liposomal doxorubicin PLD, or topotecan, also given intravenously every three weeks. During the study, participants will undergo scans and biopsies to evaluate tumor response and drug effects. Researchers will monitor safety, side effects, and various measures such as progression-free survival and overall survival for up to 40 months. Participants will have regular visits for treatment, assessments, and laboratory tests to track their health and response to the study treatments.
Actively Recruiting
Researchers are evaluating the addition of Tersolisib LY4064809STX-478 to other anti-cancer drugs as a first treatment for adults with advanced hormone receptor-positive HR and human epidermal growth factor receptor 2-negative HER2- breast cancer that has a PIK3CA genetic mutation. The study aims to assess the effectiveness and safety of this combination in people whose cancer cannot be cured by surgery alone. Participants may continue in the study as long as the treatment is helping and side effects are manageable. Participants will be randomly assigned to one of three groups two different doses of Tersolisib combined with a CDK46 inhibitor and endocrine therapy ET, or a placebo combined with the same drugs. The CDK46 inhibitor and ET are given orally or intramuscularly depending on the drug chosen by the investigator. Treatments are administered orally or by injection as appropriate. The study includes a phase 2 dose optimization portion and a phase 3 randomized, double-blind, placebo-controlled portion. During the study, participants will undergo regular assessments including scans and tests to measure tumor response and progression. Researchers will monitor overall response rate, progression-free survival, and other health outcomes for up to 5 to 7 years. Safety and drug levels in the blood will also be tracked. Participants quality of life and physical function will be evaluated using questionnaires. The total time in the study depends on individual treatment response and side effects.
Actively Recruiting
Researchers are evaluating zolbetuximab combined with pembrolizumab and chemotherapy in adults with stomach cancer or gastroesophageal junction GEJ cancer that is HER2-negative, Claudin 18.2-positive, and PD-L1-positive. The study focuses on people with locally advanced unresectable or metastatic disease who may have had prior standard treatments. This phase 3 randomized, double-blind study aims to understand how well zolbetuximab works with other therapies compared to placebo with pembrolizumab and chemotherapy. Participants receive either zolbetuximab or placebo intravenously every 2 or 3 weeks, along with pembrolizumab infusions every 3 or 6 weeks. Chemotherapy is given as either CAPOX oral capecitabine tablets and oxaliplatin infusions or mFOLFOX6 infusions of oxaliplatin, folinic acid, and 5-fluorouracil over several cycles. Treatment continues until cancer progression, intolerable side effects, or another cancer therapy is needed. Pembrolizumab may be given for up to 2 years. During the study, participants visit clinics for treatment infusions, health checks, and scans to monitor cancer changes. Medical problems and side effects are tracked, and tumor samples may be collected if treatment stops due to progression. Follow-up visits and telephone health checks continue after treatment to monitor participants health and cancer status. The study measures overall survival as the main outcome over up to 72 months.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of Mirvetuximab Soravtansine in female participants aged 18 years and older who have platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high levels of folate receptor alpha FR. The study includes two groups a randomized Phase 2 group and a hepatic impairment group, with about 110 participants expected worldwide. The purpose is to better understand how this investigational antibody drug conjugate works by targeting cancer cells carrying FR to deliver a cell-killing drug. Participants in the randomized Phase 2 group receive Mirvetuximab Soravtansine intravenously on one of two schedules either a standard dose on day 1 every 21 days or a lower dose on days 1 and 15 every 28 days. The hepatic impairment group evaluates the starting dose for participants with moderately abnormal liver function, receiving different doses on day 1 of a 21-day cycle. Treatment and monitoring continue for up to about 24 months, including dose optimization and safety assessments. During the study, participants will visit the hospital or clinic regularly for medical exams, blood tests, and scans to track treatment effects and side effects. Researchers will measure responses including corneal adverse events, tumor response rates, drug concentrations in the body, and survival outcomes. Safety is closely monitored through assessments of vital signs, laboratory values, and physical exams. The total participation time is approximately 24 months, with ongoing evaluations to determine how well the treatment works and its safety profile.
Actively Recruiting
Researchers are evaluating the safety and changes in disease activity of different treatment combinations using mirvetuximab soravtansine with carboplatin, bevacizumab, or bevacizumab alone in adult women with ovarian cancer. This phase 2 study focuses on participants confirmed to have folate receptor alpha positive tumors through a specific assay. The purpose is to assess adverse events and treatment responses across multiple treatment groups. Participants will be assigned to one of three substudies, each with different treatment arms. Treatments involve intravenous infusions of mirvetuximab soravtansine combined with bevacizumab, carboplatin, or both, with dosing variations and sequences depending on the substudy. The study duration varies from approximately 31 to 40 months based on the treatment group and includes follow-up after initial combination therapies. During the study, participants will attend regular hospital or clinic visits for medical assessments including blood tests and scans. Researchers will monitor treatment-emergent adverse events, ocular adverse events, peripheral neuropathy, lung disease, and overall and progression-free survival using standardized criteria. The safety and effectiveness of the treatments will be tracked over the entire study period, which may require a higher treatment burden than standard care.
Actively Recruiting
Researchers are investigating new treatment options for people with proficient mismatch repair pMMR endometrial cancer that is advanced or has returned after surgery. This cancer begins in the lining of the uterus and has either spread locally or to other parts of the body, making surgery not an option. The study aims to compare combining sacituzumab tirumotecan sac-TMT with pembrolizumab against pembrolizumab alone to see if it helps patients live longer without the cancer worsening. Participants first receive an Induction Phase treatment of six cycles every three weeks involving pembrolizumab plus either carboplatin or cisplatin combined with paclitaxel or docetaxel. If the cancer does not progress, they move to a Maintenance Treatment Phase where they are randomly assigned to receive pembrolizumab with sac-TMT or pembrolizumab alone. If the cancer progresses, participants may enter a Subsequent Treatment Phase with random assignment to pembrolizumab plus sac-TMT or sac-TMT alone. Treatments are given by intravenous infusion following specific dosing schedules over several months. Throughout the study, participants undergo regular assessments including scans to evaluate cancer progression, monitoring for side effects, and quality of life questionnaires. Researchers will measure progression-free survival and overall survival up to approximately 44 and 54 months respectively. The study also tracks adverse events and changes in physical and role functioning. The total participation can last up to several years with careful monitoring to assess treatment outcomes and safety.
1-10 of 33
1